First-dose study of a cancer drug taken up by tumors
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and weigh at least 60 kg
- Have signed informed consent before any study procedures
- Have small-cell lung cancer or neuroendocrine cancer, and your prior treatment has failed (or you can’t get standard options that help people live longer)
- Have good daily function (ECOG 0–1)
- Have at least one measurable tumor spot that can be followed with scans (outside the brain)
- If you have brain metastases: you must have finished brain treatment at least 2 weeks ago, be off steroid medicines for at least 7 days, and be off anti-seizure medicines for at least 7 days (or on stable doses)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This early-stage trial tests a new immunotherapy drug called BI115 in people with advanced small cell lung cancer (a fast-growing type of lung cancer). The study will check if the drug is safe and whether it helps slow or shrink the cancer.
This trial tests how well different doses of a new drug, BI 764532, are tolerated by people with a specific type of brain tumor (glioma) that has not responded to standard treatments. The drug targets a protein on the tumor cells, which may help slow tumor growth.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
Hear when a new Small Cell Lung Carcinoma (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.